Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Somatostatinoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Insulinoma 1Hodgkin Disease 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Glucagonoma 1

Interventions

pembrolizumab 39Nivolumab 15Gemcitabine 8spartalizumab 7atezolizumab 7Carboplatin 7Cyclophosphamide 6130-nm albumin-bound paclitaxel 6durvalumab 5Cisplatin 5Bevacizumab 5fludarabine 4budigalimab 4Paclitaxel 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cetuximab 4Albumin-Bound Paclitaxel 4tislelizumab 3lenvatinib 3cemiplimab 3avelumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Irinotecan 3HMPL-013 3Fulvestrant 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Panobinostat × Gastrointestinal × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡